One-carbon therapeutics AB focuses on late-stage pre-clinical development of its primary clinical drug candidate targeting MTHFD1/2 proteins regulating cancer DNA damage response and metabolism. We are scaling up for the Phase I trial expected to start during 2024. Our inhibitor is a small molecule developed for multiple oncology indications and represents a novel approach to target validated cancer vulnerabilities. We focus on KRAS-mutated solid tumors and hematological cancers based on a biomarker approach. We also plan for multiple combinations with DDR profile